Celltrion Reports Results of Regdanvimab (CT-P59) in Pre-Clinical Study Against the South African Variant (B.1.351)

Shots:

• The preclinical results have demonstrated that CT-P59 has neutralizing effect against the South African variant and showed a reduction in viral load of SARS-CoV-2 and in binding affinity against RBD in the three mutations of the South African variant
• The company has completed patient enrolment of 1,300 people in an ongoing P- III trial evaluating the efficacy & safety of CT-P59 in 13 countries including the US, Spain, and Romania
• The company will continue to investigate the neutralizing Abs and other responses to protect against current SARS-CoV-2 strains and emerging variants

Click here to­ read full press release/ article | Ref: Businesswire | Image: Celltrion